Megan Couvillion, MD
Dermatology · Houston, TXNPI 1760724157
Payments from drug & device makers
Across 731 payments — averaging $4074.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.5M
- Janssen Research & Development, LLC$406K
- Eli Lilly$371K
- Amgen$201K
- Pfizer$200K
- Biofrontera Bioscience GmbH$138K
- plus $202K from 27 others
Across 17 payments — averaging $5350.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$56K
- Nielsen Biosciences, Inc.$34K
- AbbVie$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 194 | $1,461,430 |
| Janssen Research & Development, LLC | 122 | $405,561 |
| Eli Lilly | 23 | $370,575 |
| Amgen | 15 | $201,441 |
| Pfizer | 105 | $199,821 |
| Biofrontera Bioscience GmbH | 9 | $137,764 |
| Sun Pharmaceutical Industries Inc. | 40 | $48,374 |
| Journey Medical Corporation | 5 | $45,257 |
| Endo Pharmaceuticals Inc. | 17 | $41,985 |
| Lilly USA, LLC | 38 | $29,240 |
| Incyte Corporation | 23 | $25,222 |
| Biofrontera Inc. | 6 | $3,824 |
| Dermavant Sciences, Inc. | 7 | $3,792 |
| Novartis | 30 | $954 |
| Galderma Laboratories, L.p. | 25 | $877 |
| Revance Therapeutics, Inc. | 11 | $728 |
| Johnson & Johnson | 15 | $610 |
| Sanofi | 7 | $189 |
| Merz North America, Inc. | 5 | $127 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $112 |
| LEO Pharma Inc. | 5 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| UCB, Inc. | 3 | $86 |
| Arcutis Biotherapeutics, Inc. | 3 | $67 |
| Dermira, Inc. | 2 | $60 |
| Botanix SB Inc | 2 | $30 |
| Organon | 3 | $27 |
| Krystal Biotech Inc | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $24 |
| VYNE Pharmaceuticals Inc. | 1 | $21 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Hill Dermaceuticals, Inc. | 1 | $13 |
How this compares
$2,978,453 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Houston
- Michael MigdenHouston$3.7M
- Alpesh DesaiHouston$2.7M
- Suzanne BruceHouston$2.2M
- Geeta PatelHouston$626K
- Madeleine DuvicHouston$597K
- Auris HuenHouston$323K
- Catherine PapasakelariouHouston$289K
- Anisha PatelHouston$268K
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.